Clinical Cancer Research Versailles No Abst Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strair, R. K.
Right arrow Articles by Conney, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strair, R. K.
Right arrow Articles by Conney, A.
Clinical Cancer Research Vol. 8, 2512-2518, August 2002
© 2002 American Association for Cancer Research


Clinical Trials

Administration of a Phorbol Ester to Patients with Hematological Malignancies

Preliminary Results from a Phase I Clinical Trial of 12-O-Tetradecanoylphorbol-13-acetate1

Roger K. Strair2, Dale Schaar, Lauri Goodell, Joseph Aisner, Khew-Voon Chin, Joseph Eid, Rachelle Senzon, Xiao Xing Cui, Zheng Tao Han, Beth Knox, Arnold B. Rabson, Richard Chang and Allan Conney

The Cancer Institute of New Jersey [R. K. S., D. S., J. A., K-V. C., R. S., B. K., A. B. R.], Department of Pathology [L. G.], and Division of Hematology [J. E.], Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08901; Laboratory of Cancer Research, Rutgers University, Piscataway, New Jersey 08854 [X. X. C., R. C., A. C.]; and Henan Tumor Research Institute, Zheng Zhou, Henan, People’s Republic of China 476000 [Z. T. H.]

Purpose: Phorbol esters are capable of inducing a broad range of cellular effects,including the maturation/differentiation of hematopoietic cell lines (E. Huberman and M. F. Callaham, Proc. Natl. Acad. Sci. USA, 76: 1293–1297, 1979; J. Lotem and L. Sachs, Proc. Natl. Acad. Sci. USA, 76: 5158–5162, 1979; G. Rovera et al., Proc. Natl. Acad. Sci. USA, 76: 2779–2783, 1979; H. P. Koeffler, J. Clin. Investig., 66: 1101–1108, 1980). The ability to induce this differentiation at very low concentrations stimulated investigators to administer a phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), to patients with myeloid leukemias in the People’s Republic of China (Z. T. Han et al., Proc. Natl. Acad. Sci. USA, 95: 5357–5361, 1998). The tolerability of this therapy in China prompted Phase I studies of TPA in the United States. The purpose of this report is to demonstrate the tolerance of TPA at doses that result in detectable biological activity in blood and malignant cells.

Experimental Design: TPA was administered to patients with relapsed/refractory hematological malignancies.

Results: Phenotypic effects were detected in malignant cells and TPA-associated biological activity was present in blood for up to several hours after the infusion.

Conclusions: These studies confirm the feasibility of TPA administration to humans and establish the foundation for the development of phorbol esters as therapy for patients with a variety of malignant and nonmalignant disorders.




This article has been cited by other articles:


Home page
BloodHome page
G. Gobbi, P. Mirandola, C. Carubbi, C. Micheloni, C. Malinverno, P. Lunghi, A. Bonati, and M. Vitale
Phorbol ester-induced PKC{epsilon} down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation
Blood, March 26, 2009; 113(13): 3080 - 3087.
[Abstract] [Full Text] [PDF]


Home page
GENES CELLSHome page
F. Uchiumi, G. Sakakibara, J. Sato, and S.-i. Tanuma
Characterization of the promoter region of the human PARG gene and its response to PU.1 during differentiation of HL-60 cells.
Genes Cells, December 1, 2008; 13(12): 1229 - 1247.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. L. Oliva, M. C. Caino, A. M. Senderowicz, and M. G. Kazanietz
S-Phase-specific Activation of PKC{alpha} Induces Senescence in Non-small Cell Lung Cancer Cells
J. Biol. Chem., February 29, 2008; 283(9): 5466 - 5476.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
X. Zhang, W. Li, and A. F. Olumi
Low-Dose 12-O-Tetradecanoylphorbol-13-Acetate Enhances Tumor Necrosis Factor Related Apoptosis-Inducing Ligand Induced Apoptosis in Prostate Cancer Cells
Clin. Cancer Res., December 1, 2007; 13(23): 7181 - 7190.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. V. Gavrielides, A. M. Gonzalez-Guerrico, N. A. Riobo, and M. G. Kazanietz
Androgens Regulate Protein Kinase C{delta} Transcription and Modulate Its Apoptotic Function in Prostate Cancer Cells
Cancer Res., December 15, 2006; 66(24): 11792 - 11801.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
X. Zheng, R. L. Chang, X.-X. Cui, G. E. Avila, V. Hebbar, M. Garzotto, W. J. Shih, Y. Lin, S.-E. Lu, A. B. Rabson, et al.
Effects of 12-O-Tetradecanoylphorbol-13-acetate (TPA) in Combination with Paclitaxel (Taxol) on Prostate Cancer LNCaP Cells Cultured In vitro or Grown as Xenograft Tumors in Immunodeficient Mice.
Clin. Cancer Res., June 1, 2006; 12(11): 3444 - 3451.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. M. Gonzalez-Guerrico and M. G. Kazanietz
Phorbol Ester-induced Apoptosis in Prostate Cancer Cells via Autocrine Activation of the Extrinsic Apoptotic Cascade: A KEY ROLE FOR PROTEIN KINASE C{delta}
J. Biol. Chem., November 25, 2005; 280(47): 38982 - 38991.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Nakagawa, J. L. Oliva, D. Kothapalli, A. Fournier, R. K. Assoian, and M. G. Kazanietz
Phorbol Ester-induced G1 Phase Arrest Selectively Mediated by Protein Kinase C{delta}-dependent Induction of p21
J. Biol. Chem., October 7, 2005; 280(40): 33926 - 33934.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
G. E. Avila, X. Zheng, X. X. Cui, A. D. Ryan, A. Hansson, J. Suh, A. B. Rabson, R. L. Chang, W. J. Shih, Y. Lin, et al.
Inhibitory Effects of 12-O-Tetradecanoylphorbol-13-acetate Alone or in Combination with All-trans Retinoic Acid on the Growth of Cultured Human Pancreas Cancer Cells and Pancreas Tumor Xenografts in Immunodeficient Mice
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 170 - 187.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. C. Braun, Y. Cao, S. Wang, S. H. Garfield, G. Min Hur, and P. M. Blumberg
Role of phorbol ester localization in determining protein kinase C or RasGRP3 translocation: Real-time analysis using fluorescent ligands and proteins
Mol. Cancer Ther., January 1, 2005; 4(1): 141 - 150.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
L. Y. Romanova, S. Hashimoto, K.-O. Chay, M. V. Blagosklonny, H. Sabe, and J. F. Mushinski
Phosphorylation of paxillin tyrosines 31 and 118 controls polarization and motility of lymphoid cells and is PMA-sensitive
J. Cell Sci., August 1, 2004; 117(17): 3759 - 3768.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Zheng, R. L. Chang, X.-X. Cui, G. E. Avila, S. Lee, Y. P. Lu, Y. R. Lou, W. J. Shih, Y. Lin, K. Reuhl, et al.
Inhibitory Effect of 12-O-Tetradecanoylphorbol-13-acetate Alone or in Combination with All-trans-Retinoic Acid on the Growth of LNCaP Prostate Tumors in Immunodeficient Mice
Cancer Res., March 1, 2004; 64(5): 1811 - 1820.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.